Briacell Therapeutics Corp.

Ordinary Shares International Reporting
Verified Company Profile 5/05/2017
Contact Info
  • 820 Heinz Avenue
  • Berkeley, CA 94710

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Apr 30, 2017 Interim Financial Report
CIK 0001610820
Fiscal Year End 7/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: British Columbia, Canada
Year of Inc. 2006
Employees 12 a/o May 06, 2015
Company Officers/Contacts
William V. Williams, MD CEO
Gadi Levin CFO
Farrah Dean VP, Corp. Dev.
Company Directors
Dr. Saeid Babaei Chairman
William V. Williams, MD
Martin Schmieg
Rahoul Sharan
Dr. Charles Wiseman
Service Providers
Accounting/Auditing Firm
Meyers Norris Penny, LLP
900- 50 Burnhamthorpe Road West
Sussex Centre
Mississauga, ONT, L5B3C2
Securities Counsel
Kilpatrick Townsend & Stockton LLP
607 14th Street NW
Suite 900
Washington, DC, 20005-2018
United States
Bennett Jones LLP
3400 One First Canadian Place
Toronto, ONT, M5X 1A4
Investor Relations Firm

Not Available
Company History
  • Formerly=Ansell Capital Corp. until 12-2014
BCTXF Security Details
Share Structure
Market Value1 $10,134,300 a/o Oct 20, 2017
Authorized Shares Unlimited a/o Jun 15, 2015
Outstanding Shares 91,300,000 a/o Dec 27, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 72,270,000 a/o Dec 27, 2016
Par Value No Par Value
Transfer Agent(s)
Shareholders of Record 33 a/o Jun 15, 2015
Non US Stock Exchange Listing
BCT - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 365 (100%)
Aug 15, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security